Valuation: Denali Therapeutics Inc.

Market Cap 3.08B 2.77B 2.56B 2.32B 4.33B 294B 4.38B 30.58B 12.18B 154B 11.57B 11.33B 488B P/E 2026 *
-8.51x
P/E 2027 * -8.33x
Enterprise Value 2.38B 2.13B 1.97B 1.78B 3.33B 226B 3.37B 23.56B 9.38B 118B 8.91B 8.72B 376B EV / Sales 2026 *
46.9x
EV / Sales 2027 * 17.9x
Free-Float
94.52%
Yield 2026 *
-
Yield 2027 * -
1 day+0.36%
1 week+3.27%
Current month-6.68%
1 month-8.06%
3 months-19.79%
6 months-3.84%
Current year+16.84%
1 week 18
Extreme 18.005
19.32
1 month 17.33
Extreme 17.33
21.08
Current year 15.34
Extreme 15.34
27.3
1 year 13.75
Extreme 13.75
27.3
3 years 10.57
Extreme 10.57
33.33
5 years 10.57
Extreme 10.57
56.08
10 years 10.57
Extreme 10.57
93.94
Manager TitleAgeSince
Director of Finance/CFO 52 01/05/2022
Chief Executive Officer 50 01/08/2015
Chief Tech/Sci/R&D Officer 58 06/11/2025
Director TitleAgeSince
Director/Board Member 50 01/03/2015
Director/Board Member 73 01/04/2015
Director/Board Member 68 01/04/2015
Date Insider Type Main position Quantity % Market Cap. Importance
4/9/26 Sell

Chief Technology Officer

-1,654 0.0010%
2/9/26 Sell

Director

-11,439 0.0072%
1/9/26 Sell

Founder

-2,768 0.0017%
Change 5-day change 1-year change 3-year change Capi.($)
+0.36%+3.27%+14.01%+5.99% 3.08B
+0.65%-3.36%+36.98%+60.50% 64.14B
+0.75%+2.45%+12.00%+83.49% 55.53B
+0.89%+0.99%+10.45%+100.19% 53.03B
+2.76%+0.87%+27.92%+55.07% 45.99B
+2.00%-3.39%+17.83%+119.04% 42.45B
+1.34%-2.86%+224.43%+914.08% 40.45B
+0.64%-3.95%+11.15%+45.57% 32.25B
-4.60%+47.63%+107.12%+92.73% 34.47B
-3.07%-0.71%+22.85%-11.01% 24.23B
Average +0.21%+4.00%+48.47%+146.57% 39.56B
Weighted average by Cap. +0.50%+3.49%+48.94%+158.76%

Financials

2026 *2027 *
Net sales 50.65M 45.44M 42.02M 38.05M 71.09M 4.82B 71.95M 502M 200M 2.52B 190M 186M 8.01B 131M 117M 108M 98.14M 183M 12.44B 186M 1.3B 516M 6.51B 490M 480M 20.67B
Net income -443M -398M -368M -333M -622M -42.23B -630M -4.4B -1.75B -22.1B -1.66B -1.63B -70.15B -453M -406M -376M -340M -635M -43.12B -643M -4.49B -1.79B -22.56B -1.7B -1.66B -71.63B
Net Debt -708M -636M -588M -532M -994M -67.47B -1.01B -7.03B -2.8B -35.31B -2.66B -2.6B -112B -749M -672M -621M -562M -1.05B -71.31B -1.06B -7.43B -2.96B -37.31B -2.81B -2.75B -118B
Projected Income Statement - Annual - Denali Therapeutics Inc.
Logo Denali Therapeutics Inc.
Denali Therapeutics Inc. is a biopharmaceutical company establishing a new class of biotherapeutics designed to cross the blood-brain barrier using its TransportVehicle platform. It is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (Hunter syndrome). TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A), DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, DNL628 (OTV:MAPT) for Alzheimer’s disease, and DNL952 (ETV:GAA) for Pompe disease. It is also pursuing opportunities in other disease areas including oncology.
Employees
503
Date Price Change Volume
28/10/26 US$19.29 +0.36% 1,586,249
27/10/26 US$19.22 +3.00% 1,482,167
26/10/26 US$18.66 +1.36% 726,046
23/10/26 US$18.41 -1.34% 1,005,558
22/10/26 US$18.66 -0.11% 816,745
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Denali Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
19.29USD
Average target price
35.50USD
Spread / Average Target
+84.03%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Denali Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. DNLI Stock